| Literature DB >> 32794417 |
Hesham Mohamed1,2, Caj Haglund3,4, Lauri Jouhi5, Timo Atula5, Jaana Hagström1,4,6, Antti Mäkitie5,7,8.
Abstract
Oropharyngeal squamous cell carcinoma (OPSCC) is subclassified by the World Health Organization into two different entities: human papillomavirus (HPV)-positive and HPV-negative tumors. HPV infection promotes the epithelial-to-mesenchymal transition (EMT) and transformation of keratinocyte stem cells into cancer stem cells. EMT is a crucial process in the carcinogenesis of epithelial-derived malignancies, and we aimed to study the role of its markers in OPSCC. This study consists of 202 consecutive OPSCC patients diagnosed and treated with curative intent. We examined E-cadherin, β-catenin, and vimentin expression using immunohistochemistry and compared these with tumor and patient characteristics and treatment outcome. We found that the cell-membranous expression of β-catenin was stronger in HPV-positive than in HPV-negative tumors, and it was stronger in the presence of regional metastasis. The stromal vimentin expression was stronger among HPV-positive tumors. A high E-cadherin expression was associated with tumor grade. No relationship between these markers and survival emerged. In conclusion, β-catenin and vimentin seem to play different roles in OPSCC: the former in the tumor tissue itself, and the latter in the tumor stroma. HPV infection may exploit the β-catenin and vimentin pathways in carcinogenic process. More, β-catenin may serve as a marker for the occurrence of regional metastasis.Entities:
Keywords: cancer; immunohistochemistry; p16; tissue microarray
Mesh:
Substances:
Year: 2020 PMID: 32794417 PMCID: PMC7469711 DOI: 10.1369/0022155420950841
Source DB: PubMed Journal: J Histochem Cytochem ISSN: 0022-1554 Impact factor: 2.479
Figure 1.Graphical abstract describing the workflow in this study: immunohistochemistry staining, evaluation of the scoring results with clinical and pathological data, results, and conclusions. Abbreviations: HPV, human papillomavirus; OPSCC, oropharyngeal squamous cell carcinoma.
Figure 2.Immunohistochemical staining pattern of β-catenin, E-cadherin, and vimentin in oropharyngeal carcinoma (OPSCC). (A) The cell-membranous expression of β-catenin in OPSCC (magnification, 40×). (B) The cytoplasmic expression of β-catenin in OPSCC (magnification, 40×). (C) The cell-membranous expression of E-cadherin (magnification, 40×). (D) Vimentin expression in the tumor-related stromal tissue of OPSCC is denoted by “blue stars,” whereas the tumor tissue remained negative, which is denoted by “red stars” (magnification, 20×). Scale bar: 50 µm. Abbreviation: OPSCC, oropharyngeal squamous cell carcinoma.
Figure 3.A tumor sample with different staining. (A) H&E staining (magnification, 200×). (B) The cell-membranous and cytoplasmic expression of β-catenin in OPSCC (magnification, 200×). (C) The cell-membranous expression of E-cadherin (magnification, 40×). (D) Vimentin expression (magnification, 200×). Scale bar: 50 µm. Abbreviation: OPSCC, oropharyngeal squamous cell carcinoma.
Expression of E-Cadherin and Its Association With Clinicopathological Factors in OPSCC.
| Variables | E-Cadherin Scoring | |||||
|---|---|---|---|---|---|---|
| Negative | Weak | Moderate | Strong | Total Number | ||
| Sex | ||||||
| Men | 8 | 23 | 73 | 46 | 150 | |
| Women | 2 | 7 | 24 | 19 | 52 | |
| Total | 10 | 30 | 97 | 65 | 202 | 0.414 |
| Smoking | ||||||
| Never | 1 | 3 | 14 | 8 | 26 | |
| Ex-smoker | 2 | 12 | 22 | 13 | 49 | |
| Regularly | 5 | 12 | 48 | 31 | 96 | |
| Total | 8 | 27 | 84 | 52 | 171 | 0.798 |
| Heavy drinking | ||||||
| No | 1 | 13 | 28 | 19 | 61 | |
| Previously | 1 | 3 | 15 | 5 | 24 | |
| Yes | 1 | 4 | 19 | 14 | 38 | |
| Total | 3 | 20 | 62 | 38 | 123 | 0.414 |
| HPV | ||||||
| Positive | 4 | 16 | 48 | 33 | 101 | |
| Negative | 6 | 14 | 49 | 32 | 101 | |
| Total | 10 | 30 | 97 | 65 | 202 | 0.796 |
| Grade | ||||||
| Gr1 | 0 | 1 | 8 | 9 | 18 | |
| Gr2 | 2 | 7 | 48 | 21 | 78 | |
| Gr3 | 8 | 22 | 41 | 35 | 106 | |
| Total | 10 | 30 | 97 | 65 | 202 |
|
| T class | ||||||
| T1 | 3 | 5 | 19 | 11 | 38 | |
| T2 | 2 | 11 | 40 | 23 | 76 | |
| T3 | 1 | 7 | 21 | 17 | 46 | |
| T4 | 4 | 7 | 17 | 14 | 42 | |
| Total | 10 | 30 | 97 | 65 | 202 | 0.944 |
| N class | ||||||
| N0 | 1 | 4 | 21 | 13 | 39 | |
| N+ | 9 | 26 | 76 | 52 | 163 | |
| Total | 10 | 30 | 97 | 65 | 202 | 0.370 |
| Stage | ||||||
| I–II | 0 | 1 | 19 | 10 | 30 | |
| III–IV | 10 | 29 | 78 | 55 | 172 | |
| Total | 10 | 30 | 97 | 65 | 202 | 0.101 |
| Tumor site | ||||||
| Anterior wall | 3 | 9 | 25 | 24 | 61 | |
| Lateral wall | 6 | 19 | 56 | 36 | 117 | |
| Posterior wall | 0 | 0 | 1 | 2 | 3 | |
| Superior wall | 1 | 2 | 15 | 3 | 21 | |
| Total | 10 | 30 | 97 | 65 | 202 | 0.449 |
| Cell-membranous β-catenin expression | ||||||
| Negative | 2 | 4 | 5 | 1 | 12 | |
| Weak | 3 | 5 | 15 | 8 | 31 | |
| Moderate | 4 | 10 | 41 | 15 | 70 | |
| Strong | 1 | 11 | 36 | 41 | 89 | |
| Total | 10 | 30 | 97 | 65 | 202 |
|
| Cytoplasmic β-catenin expression | ||||||
| Negative | 7 | 10 | 17 | 9 | 43 | |
| Weak | 2 | 2 | 12 | 4 | 20 | |
| Moderate | 1 | 8 | 31 | 16 | 56 | |
| Strong | 0 | 10 | 37 | 36 | 83 | |
| Total | 10 | 30 | 97 | 65 | 202 |
|
Abbreviations: HPV, human papillomavirus; OPSCC, oropharyngeal squamous cell carcinoma. Boldfaced values are statistically significant for those P < 0.05 and statistically highly significant for those P < 0.001.
Chi-square test with asymptotic p-value. **Chi-square test with exact p-value.
Expression of Vimentin and its Association With Clinicopathological Factors in OPSCC.
| Variables | Vimentin Scoring | ||||
|---|---|---|---|---|---|
| Negative | Weak | Strong | Total Number | ||
| Sex | |||||
| Men | 1 | 83 | 65 | 149 | |
| Women | 0 | 26 | 26 | 52 | |
| Total | 1 | 109 | 91 | 201 | 0.429 |
| Smoking | |||||
| Never | 0 | 11 | 15 | 26 | |
| Ex-smoker | 0 | 24 | 25 | 49 | |
| Regularly | 1 | 53 | 42 | 96 | |
| Total | 1 | 88 | 82 | 171 | 0.158 |
| Heavy drinking | |||||
| No | 0 | 29 | 32 | 61 | |
| Previously | 1 | 12 | 11 | 24 | |
| Yes | 0 | 28 | 10 | 38 | |
| Total | 1 | 69 | 53 | 123 |
|
| HPV | |||||
| Positive | 1 | 45 | 54 | 100 | |
| Negative | 0 | 64 | 37 | 101 | |
| Total | 1 | 109 | 91 | 201 |
|
| Grade | |||||
| Gr1 | 0 | 9 | 9 | 18 | |
| Gr2 | 0 | 42 | 36 | 78 | |
| Gr3 | 1 | 58 | 46 | 105 | |
| Total | 1 | 109 | 91 | 201 | 0.595 |
| T class | |||||
| T1 | 0 | 21 | 16 | 37 | |
| T2 | 1 | 45 | 30 | 76 | |
| T3 | 0 | 20 | 26 | 46 | |
| T4 | 0 | 23 | 19 | 42 | |
| Total | 1 | 109 | 91 | 201 | 0.414 |
| N class | |||||
| N0 | 0 | 20 | 19 | 39 | |
| N+ | 1 | 89 | 72 | 162 | |
| Total | 1 | 109 | 91 | 201 | 0.603 |
| Stage | |||||
| I–II | 0 | 14 | 16 | 30 | |
| III–IV | 1 | 95 | 75 | 171 | |
| Total | 1 | 109 | 91 | 201 | 0.336 |
| Tumor site | |||||
| Anterior wall | 0 | 37 | 24 | 61 | |
| Lateral wall | 1 | 58 | 57 | 116 | |
| Posterior wall | 0 | 2 | 1 | 3 | |
| Superior wall | 0 | 12 | 9 | 21 | |
| Total | 1 | 109 | 91 | 201 | 0.747 |
| Cell-membranous β-catenin expression | |||||
| Negative | 0 | 7 | 4 | 11 | |
| Weak | 0 | 21 | 10 | 31 | |
| Moderate | 0 | 41 | 20 | 70 | |
| Strong | 1 | 40 | 48 | 89 | |
| Total | 1 | 109 | 91 | 201 |
|
| Cytoplasmic β-catenin expression | |||||
| Negative | 0 | 24 | 18 | 42 | |
| Weak | 0 | 5 | 15 | 20 | |
| Moderate | 0 | 39 | 17 | 56 | |
| Strong | 1 | 41 | 41 | 83 | |
| Total | 1 | 109 | 91 | 201 | 0.447 |
| E-cadherin | |||||
| Negative | 0 | 6 | 3 | 9 | |
| Weak | 0 | 19 | 11 | 30 | |
| Moderate | 1 | 48 | 48 | 97 | |
| Strong | 0 | 36 | 29 | 65 | |
| Total | 1 | 109 | 91 | 201 | 0.251 |
Abbreviations: HPV, human papillomavirus; OPSCC, oropharyngeal squamous cell carcinoma.
Chi-square test was done with exact p-value.
Cell Membranous and Cytoplasmic Expression of β-Catenin and Their Associations With Clinicopathological Factors in OPSCC.
| Variables | Cell-Membranous β-Catenin Scoring | Cytoplasmic β-Catenin Scoring | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Negative | Weak | Moderate | Strong | Total Number | Negative | Weak | Moderate | Strong | Total Number | |||
| Sex | ||||||||||||
| Men | 11 | 20 | 54 | 65 | 150 | 34 | 16 | 37 | 63 | 150 | ||
| Women | 1 | 11 | 16 | 24 | 52 | 9 | 4 | 19 | 20 | 52 | ||
| Total | 12 | 31 | 66 | 87 | 202 | 0.687 | 38 | 21 | 55 | 82 | 202 | 0.588 |
| Smoking | ||||||||||||
| Never | 1 | 4 | 7 | 14 | 26 | 3 | 5 | 7 | 11 | 26 | ||
| Ex-smoker | 2 | 6 | 18 | 23 | 49 | 13 | 6 | 17 | 13 | 49 | ||
| Regularly | 7 | 15 | 34 | 40 | 96 | 18 | 6 | 24 | 48 | 96 | ||
| Total | 10 | 25 | 55 | 75 | 171 | 0.243 | 34 | 17 | 48 | 72 | 171 | 0.307 |
| Heavy drinking | ||||||||||||
| No | 2 | 5 | 23 | 31 | 61 | 8 | 7 | 20 | 26 | 61 | ||
| Previously | 1 | 2 | 10 | 11 | 24 | 6 | 2 | 7 | 9 | 24 | ||
| Yes | 5 | 7 | 12 | 14 | 38 | 6 | 3 | 9 | 20 | 38 | ||
| Total | 8 | 14 | 45 | 56 | 123 |
| 20 | 12 | 36 | 55 | 123 | 0.810 |
| HPV | ||||||||||||
| Positive | 3 | 14 | 26 | 58 | 101 | 20 | 13 | 27 | 41 | 101 | ||
| Negative | 9 | 17 | 44 | 31 | 101 | 23 | 7 | 29 | 42 | 101 | ||
| Total | 12 | 31 | 70 | 89 | 202 |
| 43 | 20 | 56 | 83 | 202 | 0.952 |
| Grade | ||||||||||||
| Gr1 | 1 | 1 | 5 | 11 | 18 | 3 | 1 | 5 | 9 | 18 | ||
| Gr2 | 6 | 17 | 30 | 25 | 78 | 13 | 8 | 24 | 33 | 78 | ||
| Gr3 | 5 | 13 | 35 | 53 | 106 | 27 | 11 | 27 | 41 | 106 | ||
| Total | 12 | 31 | 70 | 89 | 202 | 0.387 | 43 | 20 | 56 | 83 | 202 | 0.138 |
| T class | ||||||||||||
| T1 | 2 | 6 | 13 | 17 | 38 | 11 | 1 | 11 | 15 | 38 | ||
| T2 | 2 | 16 | 25 | 33 | 76 | 11 | 10 | 20 | 35 | 76 | ||
| T3 | 3 | 3 | 20 | 20 | 46 | 6 | 5 | 15 | 20 | 46 | ||
| T4 | 5 | 6 | 12 | 19 | 42 | 15 | 4 | 10 | 13 | 42 | ||
| Total | 12 | 31 | 70 | 89 | 202 | 0.674 | 43 | 20 | 56 | 83 | 202 | 0.224 |
| N class | ||||||||||||
| N0 | 2 | 13 | 11 | 13 | 39 | 5 | 7 | 14 | 13 | 39 | ||
| N+ | 10 | 18 | 59 | 76 | 163 | 38 | 13 | 42 | 70 | 163 | ||
| Total | 12 | 31 | 70 | 89 | 202 |
| 43 | 20 | 56 | 83 | 202 | 0.946 |
| Stage | 2 | 6 | 10 | 12 | 30 | |||||||
| I–II | 2 | 9 | 8 | 11 | 30 | 41 | 14 | 46 | 71 | 172 | ||
| III–IV | 10 | 22 | 62 | 78 | 172 | 43 | 20 | 56 | 83 | 202 | 0.357 | |
| Total | 12 | 31 | 70 | 89 | 202 | 0.121 | ||||||
| Tumor site | ||||||||||||
| Anterior wall | 3 | 10 | 20 | 28 | 61 | 14 | 7 | 14 | 26 | 61 | ||
| Lateral wall | 8 | 15 | 39 | 55 | 117 | 27 | 11 | 34 | 45 | 117 | ||
| Posterior wall | 0 | 0 | 2 | 1 | 3 | 0 | 0 | 1 | 2 | 3 | ||
| Superior wall | 1 | 6 | 9 | 5 | 21 | 0.199 | 2 | 2 | 7 | 10 | 21 | 0.118 |
| Total | 12 | 31 | 70 | 89 | 202 | 43 | 20 | 56 | 83 | 202 | ||
Abbreviations: HPV, human papillomavirus; OPSCC, oropharyngeal squamous cell carcinoma.
Chi-square test with asymptotic p-value. **Chi-square test with exact p-value.
The Relationship Between Age and the Prognostic Markers Used in the Study (E-Cadherin, β-Catenin, and Vimentin) With ANOVA.
| Sum of Squares | Difference of Freedom | Mean Square | |||
|---|---|---|---|---|---|
| E-cadherin | |||||
| Between groups | 72.849 | 3 | 24.283 | 0.240 | 0.869 |
| Within groups | 20,053.412 | 198 | 101.280 | ||
| Total | 20,126.261 | 201 | |||
| Cell-membranous β-catenin | |||||
| Between groups | 104.310 | 3 | 34.770 | 0.344 | 0.794 |
| Within groups | 20,021.951 | 198 | 101.121 | ||
| Total | 20,126.261 | 201 | |||
| Cytoplasmic β-catenin | |||||
| Between groups | 211.451 | 3 | 70.484 | 0.701 | 0.553 |
| Within groups | 19,914.810 | 198 | 100.580 | ||
| Total | 20,126.261 | 201 | |||
| Vimentin | |||||
| Between groups | 289.437 | 2 | 144.719 | 1.450 | 0.237 |
| Within groups | 19,757.510 | 198 | 99.785 | ||
| Total | 20,046.947 | 200 | |||